CONTINUING TO FOCUS ON ETHICS.
INDEPENDENT. 
MULTI-DISCIPLINARY. 
FOCUSED.

Research Ethics Boards (REBs) are independent, multi-disciplinary committees that review the ethical acceptability of research involving humans. REBs that review biomedical research generally include doctors and other members of the scientific community, as well as non-scientific members with specific expertise, including ethicists, lawyers, privacy experts and community members. The REB’s role is to safeguard the rights and welfare of the individuals who volunteer to participate in research, by ensuring that the study sponsor and the researchers have adequately considered and applied the required ethical principles into the design and conduct of the research.

The Ontario Cancer Research Ethics Board (OCREB) has radically changed the research ethics environment for multi-centre cancer trials in Ontario. OCREB is a central, expert oncology REB serving the hospitals/cancer centres in Ontario that conduct oncology clinical trials. OCREB’s centralized model means that once a study is approved by OCREB, participating study centres can submit their centre-specific applications to OCREB, and typically receive OCREB approval to conduct the study within days. This includes centres joining studies that were originally approved by OCREB months or sometimes years earlier. This model not only provides a robust ethical focus on oncology research, but also streamlines the review process, minimizes redundancy, promotes consistency, and saves the time and cost of having the study reviewed by an REB at every participating institution/study site. Since its first meeting in January 2004, OCREB has been working with researchers, institutions and sponsors to safeguard the rights and welfare of research participants in Ontario, while advancing ethically sound cancer research.

OCREB is accountable to the Ontario Institute for Cancer Research’s Board of Directors through the OCREB Governance Committee.

To learn more about OCREB, visit ocreb.ca.
CONCENTRATING ON POSITIVE CHANGE.

If last year is any indication, the ancient Greek philosophers were right when they said that “the only thing that is constant is change”. A major change for OCREB this year was the move to the Clinical Trials Ontario online system, CTO Stream. The transition began in late March with the submission of new studies in CTO Stream, while submissions related to studies in OCREB Online continued in OCREB Online. For the next six months, OCREB members, staff and research teams had the challenge of working with two online systems, and we applaud their patience and perseverance. By mid-October, all active studies from OCREB Online had been transferred into CTO Stream, and the transition was complete. There now is one online system for REB review of all multi-centre research in Ontario, not just for oncology trials. CTO Stream seamlessly enables multi-centre studies in Ontario to be reviewed by one CTO Qualified REB, and reduces the number of different REB systems that researchers, institutions and sponsors have to navigate.

At the risk of sounding like a “broken record” (we’re dating ourselves), we once again can claim that the past year was our busiest ever! The 96 new studies reviewed by OCREB in 2017 surpassed the previous record of 94 new studies in 2010, and exceeded our annual average by 32 per cent. In addition to the highest number of new studies, OCREB also reviewed the highest number overall of all other submissions (e.g., amendments, reportable events) in one year (see breakdown on page 11).
Despite the significant challenges, OCREB remained focused on its core mandate to protect research participants, and steadfast in delivering its high-quality services. And we still found time to continue collaboration efforts to streamline ethics reviews more broadly. However, as noted by our stakeholders in this year’s survey and illustrated in the metrics data (see page 12), some of our timelines suffered. We expect this to be temporary as everyone develops expertise in the new system and adjusts to the changes, and we look forward to regaining or exceeding our previous timeline targets next year.

Although members may come and go as terms end and new members are appointed, one important constant throughout the years is the expertise and dedication of the individuals who serve on OCREB. We are grateful for their passion and unfailing commitment to the protection of research participants. We also thank the OCREB staff, who expertly support the work of OCREB, as well as the Policies and Procedures Committee and the OCREB Governance Committee for their contributions to OCREB’s success. Lastly, we thank the Ontario Institute for Cancer Research and the Government of Ontario for their unwavering support over the last 14 years, allowing OCREB to focus on advancing ethically sound research for the benefit of patients in Ontario and beyond.
While OCREB’s focus is on the protection of research participants, OCREB also strives to continually improve its services. In that regard, despite the changes and challenges last year, look at what we accomplished.
Policies & Procedures Committee

Established in 2006 and comprised of OCREB members and staff, this Committee serves as an advisory group to OCREB with a mandate to investigate emerging issues, and to develop or revise policies and procedures when needed. The Committee also reviews requests for proposed institutional requirements, which typically relate to consent form language, as well as conflict of interest declarations from Researchers and from OCREB members. After review and investigation, the Committee brings its recommendations to the full Board. The Committee was expanded this year to include more diverse representation, including the addition of a community member as part of an initiative to engage community representatives in all aspects of OCREB’s work. There were two in-person/web meetings, and many email consultations throughout the year.

This past year the committee made recommendations on many issues, including but not limited to: the use of a third party tracking system for participants who are lost to follow up; paediatric consent form template language to address the use of satellite sites; the Canadian Genetic Non-Discrimination Act and the new European Union data privacy protection requirements, and their implications for research; institutional and sponsor-specific consent form language requests; reconsideration of the expectation and requirements for REBs to receive Health Canada Authorizations and Clinical Trial registration information; requests to obtain participant consent remotely; reports of protocol non-compliance; and a written response to the Health Canada request for information regarding changes to the REB approval process for medical device research.

The Committee membership was expanded this year, including the addition of a community member as part of an initiative to engage community representatives in all aspects of OCREB’s work.
The NCWG encourages broad implementation of the templates to promote harmonization and to facilitate consistency in information provided to research participants across Canada.

NATIONAL CONSENT FORM WORKING GROUP (NCWG)

The NCWG – chaired by the OCREB Research Ethics Officer – is a joint effort between OCREB and its affiliated Ontario centres, and the Canadian Cancer Trials Group (CCTG), the BC Cancer Agency (BCCA) REB, and representatives from organizations in Alberta, Saskatchewan, Ontario and Newfoundland. The mandate of the group is to develop oncology consent form templates that can be adopted nation-wide by REBs and health sciences researchers. The templates must be compliant with best practices, national standards and applicable regulations and ethics guidelines, and should align with established templates when appropriate. The NCWG encourages broad implementation of the templates to promote harmonization and to facilitate consistency in information provided to research participants across Canada.

During the past year, the NCWG developed more precise Terms of Reference, expanded its membership, and planned for the adoption of the revised US National Cancer Institute consent form template, with appropriate modifications to reflect Canadian requirements. It is anticipated that the new Canadian oncology consent form template will be released in the fall of 2018.
CONTINUING EDUCATION

REB members and staff must receive adequate initial and ongoing education and training in order to be knowledgeable in the relevant regulations, guidelines, policies and ethical principles that guide the review process. OCREB members and staff are encouraged to participate in continuing education activities such as the annual Canadian Association of Research Ethics Boards (CAREB) national conference, as well as relevant online courses and webinars. Potential OCREB members observe at least one meeting prior to being appointed, and new members participate in an orientation session, during which they receive additional resources. All members must complete the Tri-Council Policy Statement 2 (TCPS2) tutorial (Course on Research Ethics) prior to being assigned as a reviewer, and members are urged to engage in relevant ongoing educational opportunities provided by their institutions, by their professional organizations and by OCREB.

Five OCREB staff members and four OCREB members attended the annual CAREB meeting last year. Due to workload and time constraints, OCREB did not host an education retreat last year. However, in addition to education sessions conducted ad hoc at some of the OCREB meetings, Dr. Philippe Bedard was invited to speak at the January 2018 OCREB meeting. Dr. Bedard is a Medical Oncologist and the Clinical Director of the Cancer Genomics Program at the Princess Margaret Cancer Centre. His research involves early phase clinical trials and the personalization of cancer treatment based on the results of testing for DNA mutations within tumour cells. The talk included real-world experience with return of results, an important evolving area for REBs. Dr. Bedard’s presentation was recorded and made available to OCREB members.

MONTHLY WEBINARS/TELECONFERENCES

Since 2006, OCREB has been hosting monthly sessions for study staff at its affiliated oncology centres to provide education, to share noteworthy items affecting the research community and to promote dialogue on research participant protection. The sessions also provide a forum for communicating updates on relevant regulations and guidelines and their interpretation and implementation, as well as on OCREB policies, procedures and guidelines. Communication was particularly important this year with the move to CTO Stream. The 12 web/teleconference sessions last year were attended by an average of 14 centres (range 9 to 19). Summaries of the sessions are posted on the OCREB website at Monthly Centre Meetings. Although it is difficult to gauge the reach and relevance of the sessions, attendee feedback suggests that the sessions benefit their practice as research professionals, and a portion can be applied toward continuing education credits.

Since 2006, OCREB has been hosting monthly sessions for study staff at its affiliated oncology centres.
STAKEHOLDER FEEDBACK

Retiring OCREB members are invited to participate in exit surveys designed to assess their experiences in relation to workload, to their REB roles and responsibilities, and to the review processes, including the ethical criteria guiding the reviews. Responses are summarized and presented to the OCREB Governance Committee and to the OCREB members to establish areas for improvement. Three exit interviews were conducted last year. Board members also were surveyed informally at several OCREB meetings to assess their satisfaction with OCREB procedures and with the new CTO online system.

Stakeholder surveys are conducted bi-annually to assess research team and sponsor satisfaction with OCREB’s procedures and processes, and to solicit recommendations for improvement. The response rate to this year’s survey from the researcher group was 10 per cent (down from 12 per cent in 2016). Only 28 responses were received from sponsors and CROs compared to 23 in 2016. Given the low response rates, the results are difficult to interpret. The most vocal responses related to issues with timeliness and consistency, although overall feedback was positive. The majority of respondents rated the quality of OCREB reviews as good or excellent, and many singled out the team for their responsiveness, knowledge and willingness to assist the applicants. The constructive suggestions will assist our improvement efforts.
HARMONIZATION AND STREAMLINING EFFORTS

OCREB continues to actively participate in a variety of ethics-related initiatives and harmonization efforts in Ontario and Canada. This includes leading the national REB Standard Operating Procedures (SOP) Committee in addition to the NCWG. Due to workload and time constraints, as well as a recent change in the Chair of the BCCA REB, modest progress has been made in the interprovincial ethics harmonization streamlining effort. However, communication continues with B.C., and more recently with Cancer Care Manitoba.

In 2015 and 2016, the OCREB Executive Director chaired a working group that was charged with identifying a mechanism that would allow for the safe and ethical conduct of study-related activities outside of the pediatric research centres. The outcome of that effort was published in December 2017 in Pediatric Blood & Cancer (Volume 65, Issue 4): ‘Pediatric oncology clinical trial participation where the geography is vast: Development of a clinical research system for tertiary and satellite centers in Ontario, Canada’. The model supports excellence in care while ensuring the safe conduct of the research in compliance with applicable regulations and guidelines. Pediatric patients participating in Children’s Oncology Group trials at an Ontario pediatric research centre now are able to receive some study-related care closer to home.

ONLINE SYSTEM CHANGE

A huge undertaking for OCREB this year was the change in online REB submission and review systems from OCREB Online (launched in 2011) to CTO Stream (launched in 2015). The first phase of the transition began with the submission of all new studies in CTO Stream in late March. Submissions related to studies already in OCREB Online (e.g., amendments, continuing reviews, reportable events) continued to be submitted in OCREB Online. This meant that for the next six months, OCREB members, staff and research teams had to use two different online systems, while also preparing for the migration from OCREB Online, including extensive communication efforts and system testing. The final phase of the transition took place in September and October with the export from OCREB Online of 360 active studies associated with 1229 study-centres, and then importing them into CTO Stream. On October 13, CTO Stream became the sole system for submissions to OCREB. An export utility tool was developed to extract and archive the data in OCREB Online (over 700 studies associated with over 2200 study-centres), and on February 17, 2018, OCREB Online was taken offline.
The metrics data relate to the calendar year. Since two systems were in use for most of the calendar year, submissions received in OCREB Online (O2) are presented separately from those received in CTO Stream. The efforts associated with the system transition in addition to a higher volume of submissions may have had a negative impact on the timeline metrics.

Volume
OCREB received 96 new studies in 2017 compared to 84 in 2016, nine of which met the criteria for delegated review. This is the highest number of new studies ever received in a year and a 14 per cent increase over 2016. The previous record was 94 new studies in 2010 with an annual average of 77 since 2010. Of the 921 studies submitted to OCREB since its first meeting in January 2004, 408 studies associated with 1176 study-centres remained active at the end of 2017. This compares to 371 active studies with 1143 active study-centres at the end of 2016.

Once a study is up and running, it is associated with multiple post-approval submissions. These include applications from centres for approval to join an approved study, changes related to new information gathered during the conduct of the study, reports of events that occurred during the conduct of the study, reports of study progress, and notifications of study closures. In 2017, OCREB received the highest number of submissions in a year overall, for all but three application types.
OCREB received 96 new studies in 2017 compared to 84 in 2016, nine of which met the criteria for delegated review. This is the highest number of new studies ever received in a year and a 14 per cent increase over 2016.

The table below displays the volume of each application type submitted in OCREB Online in each of the past five years, and the numbers that were submitted last year in OCREB Online and in CTO Stream. The highlighted fields show the years with highest number.

<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Provinical Initial Applications/New Studies</td>
<td>60</td>
<td>70</td>
<td>59</td>
<td>92</td>
<td>84</td>
<td>22</td>
<td>74</td>
</tr>
<tr>
<td>Centre Initial Applications</td>
<td>220</td>
<td>247</td>
<td>183</td>
<td>306</td>
<td>294</td>
<td>205</td>
<td>107</td>
</tr>
<tr>
<td>Provinical Amendments</td>
<td>538</td>
<td>588</td>
<td>677</td>
<td>550</td>
<td>579</td>
<td>479</td>
<td>230</td>
</tr>
<tr>
<td>Centre Amendments</td>
<td>114</td>
<td>140</td>
<td>109</td>
<td>136</td>
<td>159</td>
<td>132</td>
<td>35</td>
</tr>
<tr>
<td>Provinical Continuing Reviews</td>
<td>261</td>
<td>314</td>
<td>286</td>
<td>270</td>
<td>310</td>
<td>267</td>
<td>78</td>
</tr>
<tr>
<td>Centre Continuing Reviews</td>
<td>770</td>
<td>945</td>
<td>901</td>
<td>886</td>
<td>1,043</td>
<td>919</td>
<td>268</td>
</tr>
<tr>
<td>Provinical Reportable Events</td>
<td>158</td>
<td>231</td>
<td>224</td>
<td>227</td>
<td>229</td>
<td>238</td>
<td>52</td>
</tr>
<tr>
<td>Centre Reportable Events</td>
<td>367</td>
<td>434</td>
<td>221</td>
<td>193</td>
<td>206</td>
<td>169</td>
<td>51</td>
</tr>
<tr>
<td>Provinical Study Closures</td>
<td>44</td>
<td>44</td>
<td>61</td>
<td>51</td>
<td>54</td>
<td>39</td>
<td>7</td>
</tr>
<tr>
<td>Centre Closures</td>
<td>121</td>
<td>166</td>
<td>216</td>
<td>156</td>
<td>163</td>
<td>108</td>
<td>47</td>
</tr>
</tbody>
</table>
| **TOTAL**                              | **2,653** | **3,179** | **2,937** | **2,867** | **3,121** | **3,527** | **+13**       |}

* Submissions in OCREB Online (O2): January 1 to March 20, 2017 for new studies, and January 1 to August 22, 2017 for all other applications.
+ Submissions in CTO Stream: March 21 to December 31, 2017 for new studies and their associated post-approval applications, and October 13 to December 31, 2017 for all other applications.
Timelines

New studies/provincial initial applications (PIAs)
OCREB reviewed 96 new studies in 2017, including nine that did not require review by the full Board – i.e., at a convened meeting. The median time from submission to approval of the 22 new studies submitted in OCREB Online (O2) between January 1 and March 20 was 91 calendar days; the median time to approval of the 74 new studies submitted in CTO Stream between March 21 and December 31 was 91.9 calendar days, which includes a median of 0.1 days in the CTO screening process prior to OCREB receipt. For comparison, the median time from submission to approval in 2016 was 78.5 calendar days (in OCREB Online).

Centre initial applications (CIAs)
OCREB received 312 CIAs in 2017. Of those, the median time from submission to approval of the 205 submitted in OCREB Online (O2) between January 1 and August 22 was 3 calendar days; the median time to approval of the 107 submitted in CTO Stream between March 21 and December 31 was 7.7 calendar days, which includes a median of 0.3 days in the CTO screening process prior to OCREB receipt. For comparison, the median time from submission to approval in 2016 was 4 calendar days (in OCREB Online).

Provincial (study-wide) amendments (PAMs)
OCREB received 709 PAMs in 2017. Of those, the median time from submission to approval of the 57 submitted in OCREB Online (O2) between January 1 and August 22 and reviewed by the full board was 56.0 calendar days, and 6 calendar days for the 422 that underwent delegated review. The median time to approval of the 32 submitted in CTO Stream between March 21 and December 31 and reviewed by full board was 65.4 calendar days, and 8.3 calendar days for the 198 that underwent delegated review. For comparison, the median approval time in 2016 was 54 and 6 calendar days for full board versus delegated reviews, respectively (in OCREB Online).

<table>
<thead>
<tr>
<th>APPLICATION TYPE/SYSTEM</th>
<th>NUMBER</th>
<th>SUBMISSION TO APPROVAL MEDIAN CALENDAR DAYS</th>
</tr>
</thead>
<tbody>
<tr>
<td>New studies/provincial initial applications (PIAs)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>OCREB Online (O2) – January 1 to March 20</td>
<td>22</td>
<td>91</td>
</tr>
<tr>
<td>CTO Stream – March 21 to December 31</td>
<td>74</td>
<td>91.9</td>
</tr>
<tr>
<td>Centre initial applications (CIAs)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>OCREB Online (O2) – January 1 to August 22</td>
<td>205</td>
<td>3</td>
</tr>
<tr>
<td>CTO Stream – March 21 to December 31</td>
<td>107</td>
<td>7.7</td>
</tr>
<tr>
<td>Provincial (study-wide) amendments (PAMs)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>OCREB Online (O2) – Full Board Review – January 1 to August 22</td>
<td>57</td>
<td>56</td>
</tr>
<tr>
<td>CTO Stream – Full Board Review - March 21 to December 31</td>
<td>32</td>
<td>65.4</td>
</tr>
<tr>
<td>OCREB Online (O2) – Delegated Review – January 1 to August 22</td>
<td>422</td>
<td>6</td>
</tr>
<tr>
<td>CTO Stream – Delegated Review – March 21 to December 31</td>
<td>198</td>
<td>8.3</td>
</tr>
</tbody>
</table>
Cost Recovery

On April 1, 2013, OCREB began charging for the initial and annual review of industry-sponsored studies. The fee structure took into consideration the amounts charged by REBs in Canada and the U.S, the average number of centres participating in each study, the review activities required over the lifecycle of a trial, and a pragmatic approach to managing the overall process. The total amount recovered each year represents approximately 30 per cent of OCREB’s overall annual operating costs. The cost model and fee structure changed with the move to CTO Stream in March 2017. CTO now is responsible for the collection and distribution of the REB review fees.

The cost model and fee structure changed with the move to CTO Stream in March 2017. CTO now is responsible for the collection and distribution of the REB review fees.
THE TEAM THAT FOCUSES ON OUR MANDATE.

OCREB MEMBERSHIP 2017-18

CHAIR
Richard Sugarman
Chair, OCREB, Ontario Institute for Cancer Research, Toronto
Member, OCREB Policies & Procedures Committee

VICE-CHAIRS
Yoo-Joung (Yooj) Ko
Vice-Chair, OCREB
Medical Oncologist, Sunnybrook Health Sciences Centre, Toronto
Member, OCREB Policies & Procedures Committee

Jacqueline Limoges
Appointed as Vice-Chair January 2018
Vice-Chair, OCREB
Professor (Nursing), Faculty of Health, Wellness and Science and REB Chair, Georgian College, Barrie
Member, OCREB Policies & Procedures Committee

MEMBERS
Natasha Alexander (alternate)
Appointed January 2018
Clinical Assistant, The Hospital for Sick Children, Toronto

James Anderson (alternate)
Appointed August 2017
Bioethicist, The Hospital for Sick Children, Toronto

Laura Bailey
Clinical Research Coordinator/Recruitment Specialist, London Health Sciences Centre, London

Patti Bambury (alternate)
Co-Coordinator, Resource Nurse, Children’s Out-patient Clinic, Grand River Hospital, Kitchener

Sally Bean
Stepped down June 2017
Senior Ethicist and Policy Advisor, Sunnybrook Health Sciences Centre, Toronto

Kate Besel
Clinical Research Associate, Sunnybrook Health Sciences Centre, Toronto

Valerie Bourada
Appointed January 2018
Research Ethics Board Manager, Children’s Hospital of Eastern Ontario, Ottawa

Savtaj Brar (alternate)
Surgical Oncologist, Sinai Health System, Toronto

Scott Bratman
Reappointed March 2018
Radiation Oncologist, Princess Margaret Cancer Centre, University Health Network, Toronto

Catriona Buick
Advanced Practice Nurse, Odette Cancer Centre, Sunnybrook Health Sciences Centre, Toronto

Left to right: Richard Sugarman, Chair, Jacqueline Limoges, Vice-Chair and Yoo-Joung (Yooj) Ko, Vice-Chair.
Lindsay Carlsson  
Clinical Research Coordinator,  
Princess Margaret Cancer Centre,  
University Health Network, Toronto

Stephanie Chadwick (alternate)  
Appointed August 2017  
Nurse Practitioner, Odette Cancer Centre, Sunnybrook Health Sciences Centre, Toronto

Carol Cheung  
Pathologist, Princess Margaret Cancer Centre, University Health Network, Toronto  
Member, OCREB Policies & Procedures Committee

Elvina Chow (alternate)  
Lawyer, California  
Member, OCREB Policies & Procedures Committee

Christine Elser (alternate)  
Medical Oncologist, Princess Margaret Cancer Centre, University Health Network and Mount Sinai Hospital, Toronto

Joseph Ferenbok  
Stepped down July 2017  
Director Translational Research Program, University of Toronto

Graeme Fraser  
Stepped down March 2018  
Hematologist, Juravinski Cancer Centre, Hamilton

Lee Ann Gallant  
Stepped down October 2017  
Pediatrician, Gallant Medical Clinic, Toronto

Janet Gammon  
Reappointed March 2018  
Pediatric Oncology Nurse (retired), Toronto

Ronald Grant (alternate)  
Pediatric Medical Oncologist, The Hospital for Sick Children, Toronto

Rebecca Greenberg (alternate)  
Stepped down December 2017  
Bioethicist, The Hospital for Sick Children, Toronto

Karen Haas  
Community Representative, Brampton

Janice Hodgson (alternate)  
Term completed December 2017  
Community Representative, Newmarket

Michael Huynh  
Lawyer, Toronto  
Member, OCREB Policies & Procedures Committee

Irene Karam (alternate)  
Appointed January 2018  
Radiation Oncologist, Odette Cancer Centre, Sunnybrook Health Sciences Centre, Toronto

Swati Kulkarni (alternate)  
Medical Oncologist, Windsor Regional Hospital Cancer Program, Windsor

Eric Leung (alternate)  
Term completed December 2017  
Radiation Oncologist, Sunnybrook Health Sciences Centre, Toronto

Alexander Louie (alternate)  
Radiation Oncologist, London Health Sciences Centre, London

Arif Manji (alternate)  
Pediatric Medical Oncologist, St Boniface Regional Cancer Centre, Southlake Regional Health Centre, Newmarket and The Hospital for Sick Children, Toronto

Mihaela Mates  
Medical Oncologist, Cancer Centre of Southeastern Ontario, Kingston

Andrea Mattiussi (alternate)  
Clinical Pharmacist, The Hospital for Sick Children, Toronto

Michelle Mullen  
Bioethicist, Children’s Hospital of Eastern Ontario, Ottawa  
Member, OCREB Policies & Procedures Committee

Krista Naccarato  
Appointed April 2017  
Business Coordinator, Clinical Trials, Windsor Regional Hospital, Windsor

Carolyn Nessim  
Surgical Oncologist, The Ottawa Hospital, Ottawa

Antonia Palmer  
Reappointed March 2018  
Community Representative, Mississauga  
Member, OCREB Policies & Procedures Committee

Sameer Parpia (alternate)  
Biostatistician, McMaster University, Ontario Clinical Oncology Group, Hamilton

Elizabeth Scheid  
Term completed December 2017  
Research Associate, Tumour Immunotherapy Program, Princess Margaret Cancer Centre, University Health Network, Toronto

Elizabeth Strelow (alternate)  
Medical Oncologist, Trillium Health Partners, Credit Valley Site, Toronto

George Tomlinson  
Biostatistician, University Health Network and Mount Sinai Hospital, Toronto

Deborah Van Seters  
Appointed September 2016  
Community Representative, Waterloo

Lisa Wang (alternate)  
Biostatistician, Princess Margaret Cancer Centre, University Health Network, Toronto

Sheila Weitzman  
Reappointed March 2018  
Pediatric Medical Oncologist, The Hospital for Sick Children, Toronto

John Wiernikowski  
Term completed March 2018  
Clinical Pharmacist, Pediatrics, McMaster Children’s Hospital, Hamilton

Jason Yu (alternate)  
Medical Oncologist, Royal Victoria Regional Health Centre, Barrie
OCREB GOVERNANCE COMMITTEE

CHAIR
James (Jim) Wright
Appointed May 2017
Associate Professor, McMaster University
Division Head, Radiation Oncology,
Juravinski Hospital and Cancer Centre,
Hamilton

MEMBERS
Derek Cathcart
Partner, First Canadian Investment Properties
Managing Partner, Cathcart & Associates,
Toronto

Christopher Henley
Reappointed May 2017
Founder and President, Henley Capital Corporation, Toronto

Laurel Evans
Appointed May 2017
Director, Research Ethics, University of British Columbia, Vancouver

Nancy Walton
Appointed May 2017
Associate Professor, Daphne Cockwell School of Nursing, Ryerson University
Chair, Research Ethics Board, Women’s College Hospital, Toronto

EX-OFFICIO MEMBERS
Richard Sugarman
Chair, OCREB
Yooj Ko
Vice-Chair, OCREB
Jacqueline Limoges
Vice-Chair, OCREB
Janet Manzo
Executive Director, OCREB

OCREB OFFICE PERSONNEL

TOP ROW
Victoria Shelep
Research Ethics Coordinator
Katherine Zeman
Research Ethics Coordinator
Cindy Sandel
Research Ethics Coordinator

BOTTOM ROW
Alison van Nie
Research Ethics Officer
Chair, OCREB Policies & Procedures Committee
Aurora de Borja
Senior Research Ethics Coordinator
Member, OCREB Policies & Procedures Committee
Janet Manzo
Executive Director
Member, OCREB Policies & Procedures Committee
FOR MORE INFORMATION

Ontario Cancer Research Ethics Board
c/o Ontario Institute for Cancer Research

MaRS Centre
661 University Avenue, Suite 510
Toronto, Ontario M5G 0A3

416-673-6649

ocurrency.ca